Meitav Dash Investments Ltd. Has $590,000 Position in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Meitav Dash Investments Ltd. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 123.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,053 shares of the biopharmaceutical company’s stock after purchasing an additional 9,987 shares during the quarter. Meitav Dash Investments Ltd.’s holdings in Pfizer were worth $590,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the stock. Sound View Wealth Advisors Group LLC raised its position in Pfizer by 4.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 119,967 shares of the biopharmaceutical company’s stock valued at $3,923,000 after acquiring an additional 5,657 shares in the last quarter. Legacy Financial Advisors Inc. raised its position in shares of Pfizer by 26.4% in the second quarter. Legacy Financial Advisors Inc. now owns 25,931 shares of the biopharmaceutical company’s stock valued at $848,000 after purchasing an additional 5,423 shares during the period. Rafferty Asset Management LLC raised its position in shares of Pfizer by 141.4% in the second quarter. Rafferty Asset Management LLC now owns 133,965 shares of the biopharmaceutical company’s stock valued at $4,381,000 after purchasing an additional 78,480 shares during the period. Wintrust Investments LLC raised its position in shares of Pfizer by 36.1% in the second quarter. Wintrust Investments LLC now owns 26,082 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 6,919 shares during the period. Finally, Estate Counselors LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $371,000. Institutional investors and hedge funds own 70.20% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada restated a “buy” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, July 20th. JPMorgan Chase & Co. lowered their price objective on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, June 1st. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price objective on the stock. in a research note on Monday, May 4th. ValuEngine downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday, July 30th. Finally, UBS Group raised their price objective on shares of Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $38.95.

In other Pfizer news, Director Ronald E. Blaylock purchased 13,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the transaction, the senior vice president now directly owns 7,542 shares of the company’s stock, valued at $272,492.46. The disclosure for this sale can be found here. Insiders own 0.08% of the company’s stock.

PFE traded up $0.12 during trading on Friday, reaching $38.84. 658,942 shares of the company’s stock were exchanged, compared to its average volume of 25,516,400. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $40.97. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $36.86 and a 200 day moving average price of $35.64. The company has a market capitalization of $212.61 billion, a P/E ratio of 15.37, a PEG ratio of 3.08 and a beta of 0.74.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The company had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter in the previous year, the company earned $0.80 EPS. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.89 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be issued a $0.38 dividend. The ex-dividend date is Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.91%. Pfizer’s dividend payout ratio is 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a recession?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply